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A B S T R A C T
Brain-derived neurotrophic factor (BDNF) is a protein often studied in psychiatric populations. Commercial
ELISA kits have been validated for measuring BDNF in blood plasma and serum, but blood collection is an
invasive method which cannot always be used. The aim of this pilot study was to explore the noninvasive
alternative of measuring BDNF in saliva. Three diﬀerent commercial ELISA kits were used to analyze parallel
plasma and saliva samples from six healthy adults. In total 33 plasma and 33 saliva samples were analyzed
according to manufacturers’ standard protocols. BDNF was successfully measured in plasma in two of the three
kits, of which the results correlated highly (rs =.88). BDNF could not be measured reliably in saliva. The results
of this pilot study suggest that techniques of commercial BDNF kits may not be ready for noninvasive saliva
measurements, which limits the sampling frequency and settings.
1. Introduction
Brain-derived neurotrophic factor (BDNF) is a protein responsible
for synaptic plasticity. Diﬀerences in BDNF levels have been associated
with several psychiatric disorders, such as Major Depressive Disorder,
bipolar disorder and schizophrenia (Autry and Monteggia, 2012;
Munkholm et al., 2016; Polyakova et al., 2015; Soares et al., 2016;
Toll and Mané Santacana, 2015; Wang et al., 2016). In these studies
BDNF levels were determined in blood serum or plasma. Blood
collection from patients or participants is an invasive method, and
poses restrictions to the frequency of sampling and the environments in
which sampling can take place. The background of this pilot study is a
project in which anhedonia was investigated in young adults and
interventions were developed to help them regain pleasure (Roekel
et al., 2016). Because of its associations with depression, BDNF was
considered a relevant protein. Since one of the interventions took place
in a situation in which blood collection was not possible, the possibi-
lities of the noninvasive and cost-eﬃcient alternative of measuring
BDNF in saliva were explored in a small pilot study. Although not to be
interpreted as conclusive evidence, other researchers interested in
measuring BDNF in saliva may beneﬁt from the results of this pilot
study. Noninvasive alternatives to blood BDNF would be relevant for,
among others, research on BDNF ﬂuctuations in psychiatric patient
groups, and in the upcoming ﬁeld of ecological momentary assessment
(EMA), which involves frequent assessment of emotions, behaviors and
social contexts over time in one's naturalistic environment (Shiﬀman
et al., 2008), and has already been extended to salivary biomarkers
cortisol and alpha-amylase (Bitsika et al., 2015; Booij et al., 2016).
It has been demonstrated by means of immunoblotting that BDNF is
present in human saliva (Mandel et al., 2009). However, whereas
several commercial ELISA kits have been validated for measuring BDNF
in plasma and serum, up until now none has been validated for
measuring BDNF in saliva. In 2011 Mandel and colleagues assessed
the possibilities of quantifying BDNF in saliva using commercial ELISA
kits (Chemicon and Promega), but the BDNF levels rarely reached the
minimum detection level of the kits (Mandel et al., 2011). Mandel and
colleagues suggested that this was most likely due to matrix complexity,
and decided not to use the commercial kits, but to develop a sandwich
ELISA optimized for measuring BDNF in saliva themselves. In recent
years, six studies reported to have successfully quantiﬁed BDNF in
saliva by using commercial ELISA kits (de Souza et al., 2014, 2012; Ikai
et al., 2014; Matsuki et al., 2014; Saruta et al., 2012; Tirassa et al.,
2012). However, even reported BDNF levels for healthy young adults
(Matsuki et al., 2014; Saruta et al., 2012; Tirassa et al., 2012) were very
diverse, mean levels ranging from 9 pg/mL to 400 pg/mL. The studies
used diﬀerent ELISA kits and diﬀerent procedures for collecting, storing
and processing; and in most studies BDNF levels below the minimum
detection threshold were interpreted as true results rather than
discarded as unreliable results. See Table 1 for a comparison of the
ELISA kits and procedures used in the six previous studies, as well as of
http://dx.doi.org/10.1016/j.psychres.2017.04.034
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the mean BDNF levels that were reported. It thus remains unclear
whether BDNF in saliva can be quantiﬁed reliably by using commercial
ELISA kits.
In our study, we aimed to compare salivary BDNF with BDNF in
plasma. As opposed to BDNF in serum, which has been reported not to
be associated with salivary BDNF (Mandel et al., 2011; Tirassa et al.,
2012), correlations between salivary BDNF and BDNF in plasma have
not been studied in humans to date. Plasma BDNF levels reﬂect the
momentary circulation of BDNF. Serum BDNF is determined by the sum
of plasma BDNF and BDNF released from the platelets in serum
(Montag, 2014; Polyakova et al., 2015), which have a life-span of
about ten days and can accumulate or store BDNF (Dale, 1997).
Therefore, serum BDNF is likely to reﬂect relatively stable or long-term
BDNF levels, and plasma BDNF more momentary or short-term BDNF
levels (Bus, 2014; Montag, 2014; Polyakova et al., 2015). Experiments
in rats have shown that in situations of acute stress BDNF in the
submandibular salivary gland may aﬀect plasma BDNF levels
(Tsukinoki et al., 2007).
Developing own methods for measuring BDNF in saliva, as Mandel
and colleagues did, is not feasible for most researchers. Salivary BDNF
would be accessible for many more researchers if commercial kits could
be used for quantiﬁcation. Because of the inconsistent previous results
and ongoing technical developments during the past years, we con-
ducted a pilot study in which three diﬀerent commercial ELISA kits
were used to measure BDNF in plasma and saliva. Main aims of the
study were to explore the feasibility of quantifying BDNF in saliva with
commercial ELISA kits when following the manufacturers’ standard
protocols, a comparison between the diﬀerent ELISA kits, and a
comparison between plasma and saliva levels.
2. Materials and methods
2.1. Subjects
From six participants, one male (age 43, non-smoking) and ﬁve
females (age 63, non-smoking; age 28, smoking; age 51, non-smoking;
age 37, non-smoking; and age 36, non-smoking), blood and saliva were
collected. All participants were healthy and free of medication. From
the ﬁrst three participants (study 1), blood and saliva were collected in
the morning on ﬁve consecutive days, resulting in a total of ﬁve blood
and ﬁve saliva samples per participant. From the other three partici-
pants (study 2) blood and saliva were collected three times a day on two
diﬀerent days, with one resting day in between, resulting in a total of
six blood and six saliva samples per participant. Participants were
treated in accordance with the Declaration of Helsinki, and written
consent was acquired from all participants.
2.2. Fasting procedures
There is evidence that eating and drinking prior to sample collection
increases BDNF levels in serum (Bus et al., 2011) and it is generally
recommended to avoid eating, drinking and tooth brushing prior to
collection of saliva samples (Salimetrics LLC Company, 2012; Wong,
2009). Therefore, it would be best for participants to adhere to a fasting
protocol prior to saliva and plasma collection. However, fasting is not
possible in all circumstances, particularly if multiple samples per day
are collected, and recommended fasting periods diﬀer. We therefore
used feasible fasting procedures, adapted to the time of the day, and
around noon we tested two diﬀerent conditions, because around noon it
may be most diﬃcult to adhere to a fasting protocol. In study 1, blood
and saliva samples were collected after overnight fasting (no eating,
drinking or brushing teeth). In study 2, morning blood and saliva
samples were collected after overnight fasting and the late afternoon
samples after two hours of fasting. On the ﬁrst day the sample around
noon was collected after two hours of fasting, on the second day after
30 min of fasting.
2.3. Blood collection
Study 1. Blood collection took place at ﬁve consecutive days, in the
morning at home within half an hour after waking up, using standard
sterile techniques. Blood was collected by venipuncture in 10 mL EDTA
tubes (BD Biosciences, Franklin Lakes, NJ, USA). Samples were stored
in a cooling bag (~8 °C) immediately after collection, transferred to the
laboratory, centrifuged at 1650×g at 4 °C for 10 min. Plasma samples
were aliquoted and stored at −80 °C within one hour after collection.
Study 2. Blood collection took place at the University Medical
Center Groningen, three times a day on two diﬀerent working days: in
the morning around 8:30, around noon and in the afternoon around
16:15, using standard sterile techniques. Blood was collected by
venipuncture in 4 mL EDTA tubes. Samples were transferred to the
laboratory within ﬁve minutes, centrifuged at 1400×g at 4 °C for
10 min. Samples were aliquoted and stored at −80 °C within half an
hour after collection.
2.4. Saliva collection
Study 1. Saliva was collected in the morning right before blood
collection. Following the recommendations by Mandel and colleagues
we used a passive drooling method instead of cotton-based salivettes to
collect saliva, because the use of salivettes may result in decreased
levels of salivary BDNF (Mandel et al., 2011). Participants were
instructed to tilt their head forward and pool saliva in their mouth.
When a suﬃcient amount of saliva was pooled, participants were asked
to drool in a cryovial (Salimetrics, Carlsbad, CA, USA). Samples were
stored in a cooling bag (~8 °C) immediately after collection, transferred
to the laboratory, centrifuged at 1650×g at 4 °C for 10 min. Samples
were aliquoted and stored at −80 °C within one hour after collection.
Study 2. Saliva was collected right after blood collection, by passive
drooling. Participants were instructed to sit down about 5 min after
blood collection and drool into a 20 mL glass vial (PerkinElmer,
Waltham, MA, USA) until a 1.5 mL marker was reached. Samples were
transferred to the laboratory within ﬁve minutes, centrifuged at
1400×g at 4 °C for 10 min. Samples were aliquoted and stored at
−80 °C within half an hour after collection.
2.5. Procedures ELISA assays
All 33 plasma samples and 33 saliva samples were analyzed in three
diﬀerent commercial ELISA kits: (1) R & D DBD00 (R &D Systems,
Minneapolis, MN, USA), (2) LSBio LS-F2402 (LSBio, Seattle WA, USA),
and (3) Millipore Chemikine CYT306 (Merck Millipore, Billerica, MA,
USA). For sensitivity and detection ranges see Table 2. All kits were
validated for human plasma, serum and cell culture supernatants, but
not for saliva. Accordingly, the ELISA protocols contained instructions
for plasma analyses, but no speciﬁc instructions for saliva. Both the
Table 2
Sensitivity and detection ranges of the ELISA kits used in this study, as provided by the
manufacturers.
Kit 1 Kit 2 Kit 3
Manufacturer R &D LSBio Merck Millipore
Kit type Sandwich ELISA Sandwich ELISA Sandwich ELISA
Serial number DBD00 LS-F2402 CYT306
Sensitivity 20 pg/mL 31.2 pg/mL 15 pg/mL
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R&D kit and the Millipore kit had already been used in previous studies
to measure BDNF in saliva (Ikai et al., 2014; Matsuki et al., 2014; Saruta
et al., 2012; Tirassa et al., 2012), see also Table 1. The LSBio kit was
selected based on the manufacturer's protocol which contained clear
instructions and suggested good applicability in our lab.
All plasma analyses were performed according to standard protocol,
with the exception that standards and samples were added to the wells
in single measures. We did not analyze the samples in duplicate,
because we were not interested in the speciﬁc individual results but
merely in more general patterns of results that could inform us whether
BDNF can be quantiﬁed in saliva while using commercial ELISA kits
according to the manufacturers’ protocols. All saliva analyses were
performed according to the plasma and serum protocol, with the
exceptions that saliva samples were not diluted, and that the saliva
standard was based on the diluent that performed best in internal lab
tests for construing saliva standards, i.e, a Tris-NaCl-γ-globuline buﬀer
(0.1 mM Tris/HCl, pH 8.0, 0.1 mM NaCl, 1 g/L bovine γ-globulin
(Sigma-Aldrich, St. Louis, MO, USA)). For each kit two sets of standards
were used, one for plasma and one for saliva. It was unclear what BDNF
concentrations to expect in plasma, therefore diﬀerent dilutions were
used for the plasma samples. For the R &D kit a dilution of 1:20 was
used and for the LSBio and the Millipore kit a dilution of 1:2. Since low
BDNF concentrations in saliva were expected, saliva samples were not
diluted. Weighted 4 parameter logistic (4PL) nonlinear regression
models were used for ﬁtting the standard curves. Standard curves are
presented together with the results in Fig. 1 (see Results).
2.6. Statistical analyses
Whether the ELISA kits had functioned properly was evaluated by
inspecting whether standard curves could be plotted and whether
results were within the detection range of the kits. Next, mean BDNF
concentrations in plasma and saliva were compared between the three
kits, and Spearman correlation coeﬃcients between the diﬀerent ELISA
kits were calculated. Finally, the correlation between BDNF levels in
blood and saliva was evaluated.
3. Results
Standard curves could be plotted for BDNF in plasma and in saliva
for the R &D and LSBio kits. The Millipore kit could be made operable
for neither plasma nor saliva, that is, no standard curve could be
plotted. A second attempt with a new Millipore kit yielded the same
result. Therefore only the results of the R & D and LSBio kits are
provided in this section.
While almost all plasma results lay within the detection range of the
R &D and LSBio kit, no saliva sample fell within the range of the
calibrated standard curve and the majority did not even exceed the
level of the blank (Table 3 and Fig. 1). BDNF in saliva could not be
quantiﬁed by either kit. The estimated plasma BDNF levels of the two
ELISA kits correlated highly (rs =.88, p< .001), the mean concentra-
tions diﬀered by almost a factor ten. Because of the lack of valid saliva
results it was not possible to calculate the correlation between BDNF in
plasma and in saliva.
Fig. 1. Standard curves and results of ELISA analyses of BDNF in plasma and saliva. Results of the plasma and saliva analyses are presented for the R &D and LSBio ELISA kits separately.
Plasma results are presented in panels A (R & D) and B (LSBio) and saliva results are presented in panels C (R & D) and D (LSBio). Weighted 4 parameter logistic (4PL) nonlinear regression
models were used for ﬁtting the standard curves.
C. Vrijen et al. Psychiatry Research 254 (2017) 340–346
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4. Discussion
By far most of the saliva samples did not exceed blank level, which
means that no BDNF concentrations were measured. The saliva samples
that did exceed blank level still did not reach the lowest concentration
of the calibrated standard curve and can therefore not be considered
reliable. Our data thus suggest that it may be impossible to use
commercial ELISA kits according to manufacturers’ protocols to reliably
quantify BDNF in saliva to date. These results are in agreement with
Mandel et al. (2011) but not with de Souza et al., (2014, 2012), Ikai
et al. (2014), Tirassa et al. (2012), Saruta et al. (2012) and Matsuki
et al. (2014), who reported to have successfully quantiﬁed BDNF in
saliva using commercial ELISA kits. Diﬀerences in interpretation of
results below the minimum detection level seem to be at least a partial
explanation. Whereas de Souza et al., (2014, 2012), Ikai et al. (2014)
and Matsuki ( et al. (2014) extrapolated BDNF levels beyond the
minimum detection level of the calibrated standard curve, in Mandel
et al. (2011) and in our study, BDNF levels beyond the minimum
detection level were discarded as unreliable. Saruta et al. (2012) and
Matsuki et al. (2014) further reported a minimum detection level
of< 4 pg/mL, while the manufacturer's protocol mentions a minimum
detection level of 15 pg/mL. Neither Tirassa et al. (2012) nor Saruta
et al. (2012) reported on how results below the minimum detection
level were handled. It should be noted that the reported mean BDNF
levels for healthy young adults varied considerably, even though Saruta
et al. (2012) and Matsuki et al. (2014) used the same ELISA kits.
Altogether this suggests that commercial BDNF kits may not yet be
suﬃciently sensitive to measure BDNF reliably in saliva. This is
conﬁrmed by the fact that at this moment no ELISA manufacturers
have claimed to have validated their kits for measuring BDNF in saliva.
Results for plasma were, as expected, more promising. Almost all
results were within the detection ranges of the kits and the high
correlation between the two ELISA kits indicates that a similar
construct is measured by both. Absolute BDNF levels showed large
diﬀerences between kits and cannot be compared, because companies
use their own BDNF standards and often do not refer to a more
objective standard. From the three ELISA kits we assessed, only the
R & D protocol contains a statement about the purity of their standard
compared to the World Health Organization (WHO) human BDNF
standard and how to convert results. To allow for more meaningful
interpretations of absolute BDNF levels, it is essential that more
manufacturers provide this type of information.
The goal of our study was to assess whether BDNF in saliva can be
measured by following standard protocols of commercial kits, without
adapting or optimizing the protocol. This is at the same time a strength
and a limitation of this study. It is a strength since it mirrors the
approach that would often be followed in psychiatric research, yet it
leaves unanswered whether we would have succeeded to measure
BDNF in saliva if we had experimented with longer incubation times,
the amount of sample material, or made other adaptations to manu-
facturers’ protocol. Furthermore, standards and samples were not
analyzed in duplo and therefore, although the analysts who conducted
the analyses were well-trained, the possibility of pipetting mistakes
cannot be excluded. Another limitation is the small number of subjects
participating in our study, i.e., ﬁve females and one male. That being
said, because of our clear patterns of results for saliva we do not
consider it to be likely that our conclusions have been fundamentally
inﬂuenced by pipetting mistakes and do not expect that including more
participants or making minor adaptations to the manufacturers’ proto-
cols would change results radically. A ﬁnal limitation is that the
Millipore kit could not be made operable for plasma or saliva. And
although this too exempliﬁes the type of problems encountered when
doing this kind of research, it is currently unknown whether this was
due to mistakes inside our laboratory or malfunctioning kits.
To conclude, the results of this pilot study tentatively suggest that
techniques of commercial BDNF kits are not ready for noninvasive
saliva measurements to date, which limits the conditions in which
sampling can take place. Because of the beneﬁts of noninvasive and cost
eﬀective methods for measuring BDNF, our hopes are that it will be
possible to measure BDNF in saliva by using commercial kits in the near
future. An alternative approach, which is currently being developed, is
to collect blood in less invasive ways (e.g. Hemolink, Tasso Inc, Seattle,
WA, USA), which allows the use of commercial ELISA kits that have
already been validated for measuring BDNF in plasma and serum. If
successful, both approaches are expected to be of great signiﬁcance to
studies in psychiatry.
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